Medizone International Announces an Agreement with JRH Biosciences to Develop Commercial Treatment of Bovine Serum NEW YORK CITY - April 22, 1997 - Medizone International, Inc. ("Medizone") (OTC.BB:MZEI.U) announced today that it has entered into an agreement with JRH Biosciences, headquartered in Lenexa, Kansas, a CSL Limited Company. The purpose of the agreement is to investigate, develop, and ultimately license Medizone's patented viral decontamination process specifically for the treatment of bovine serum. JRH Biosciences is a global supplier of sera and cell culture media products to biotech and biopharmaceutical companies. This agreement, which will be implemented at the JRH Biosciences facility in Lenexa, Kansas, is structured in a three-tier program: 1) validate that Medizone's decontamination process inactivates pathogens while maintaining the biological characteristics of the treated serum; 2) "scale-up" a device that delivers Medizone's process and accommodates commercial volumes of biological fluids; and 3) commercially license Medizone's technology for this application. Dr. Joseph S. Latino, Medizone's President, said, "This agreement marks a highly significant step for us, the first potential commercial application of Medizone's patented technology, and could lead to a revenue stream for the Company. The scientific acknowledgement and partnership with a worldwide leader in the field of bovine serum production should eventually lead to the Company's transformation from a research and development company to a commercial entity." The preliminary groundwork for the agreement with JRH Biosciences was developed through Medizone's subsidiary, Medizone New Zealand Ltd. (MNZL), therefore revenues derived from the licensing of Medizone's technology will be distributed as described in both licensing and managing agent agreements between Medizone and MNZL. Medizone is developing Medizone, an ozone-based treatment for diseases caused by lipid enveloped viruses, including Acquired Immunodeficiency Syndrome (AIDS), Hepatitis B, and Herpes; and is also developing its patented technology for the decontamination of blood and blood products.